Smoldering multiple myeloma is a clinical entity that does not require immediate treatment, but selected patients with high-risk disease require more frequent follow-up. Monoclonal gammopathies represent a broad differential diagnosis and require a thorough evaluation for clinical significance. In this review, we focus on treatment strategies for patients with monoclonal gammopathies that are not multiple myeloma, including smoldering multiple myeloma, light-chain amyloidosis, and Waldenström macroglobulinemia.
CARDINAL CHAINS LEVEL 100 HOW TO
Recognition has become all the more important as we understand how to triage the 4% to 9% of patients with monoclonal gammopathies depending on age, with the goal of limiting overdiagnosis and misdiagnosis. Early recognition of monoclonal gammopathies along with a careful workup are essential in determining the next steps in the care of a given patient.
This change has created a challenge for patients and clinicians, as a monoclonal gammopathy may be a harbinger not of multiple myeloma but of other lymphoproliferative disorders such as light-chain amyloidosis and Waldenström macroglobulinemia. Once accepted as a possible precursor condition to multiple myeloma, monoclonal gammopathies as an entity are now associated with many renal, neurologic, and dermatologic disorders of clinical significance. Our knowledge of monoclonal gammopathies is continuously evolving.
0 kommentar(er)
